The primary antidote for arsenic poisoning is a chelation agent called dimercaprol, better known by its wartime name BAL (British Anti-Lewisite). Developed during World War II to counter an arsenic-based chemical weapon, BAL remains the go-to treatment for severe acute arsenic ingestion. Two newer chelation drugs, DMSA and DMPS, have since emerged as alternatives with fewer side effects. But chelation alone rarely saves a life; the full treatment picture involves aggressive supportive care, and the clock starts ticking from the moment arsenic enters the body.
How Chelation Agents Neutralize Arsenic
Arsenic is dangerous because it latches onto sulfur-containing groups in your body’s proteins and enzymes, disrupting critical processes. It inhibits pyruvate dehydrogenase, an enzyme your cells need to produce energy, by binding to sulfur-rich sites on the enzyme itself.1PubMed. Reactive oxygen species are involved in arsenic trioxide inhibition of pyruvate dehydrogenase activity One form of arsenic, arsenate, mimics phosphate so closely that it can slip into reactions where phosphate belongs and interfere with your cells’ energy production at a more fundamental level.2ACS Publications. Arsenic Binding to Proteins
Chelation agents work by offering arsenic a more attractive binding target than your own tissue. These drugs contain sulfur-based chemical groups that grab arsenic ions and lock them into a stable, water-soluble complex. Once bound to the chelator, arsenic can no longer interact with enzymes or proteins and is flushed out through the kidneys or bile. The word “chelation” comes from the Greek word for claw, which captures the idea nicely: the drug molecule wraps around the metal atom and holds on.
BAL, the Original Wartime Antidote
BAL was developed during World War II specifically to protect soldiers from Lewisite, a blistering chemical warfare agent built around arsenic. Allied researchers at Oxford created it as a countermeasure, and it proved effective enough that it became standard military issue.3PubMed. British anti-Lewisite (dimercaprol): an amazing history After the war, BAL transitioned into civilian medicine as a treatment for arsenic, mercury, and lead poisoning.
BAL is given by deep intramuscular injection, not by mouth. The injections are painful, and the drug carries a significant side-effect profile. It can cause nausea, vomiting, headache, a burning sensation in the mouth and eyes, elevated blood pressure, and a rapid heart rate. In some patients, it produces a feeling of severe anxiety or chest tightness. These side effects are tolerable when someone is dying of arsenic poisoning, but they make BAL a poor choice for less critical situations or long treatment courses. The drug also has a notable limitation: it is dissolved in peanut oil, so patients with peanut allergies face additional risk.
Despite these drawbacks, BAL has remained a mainstay of arsenic poisoning treatment for over half a century because it is widely available, well-studied, and effective at pulling arsenic out of tissues when given early.4PubMed Central. Chelation in metal intoxication For severe acute poisoning where a patient cannot take oral medication, it is still often the first drug administered.
DMSA and DMPS, the Newer Alternatives
The serious side effects of BAL pushed researchers to develop better options. In the late 1950s, scientists in the Soviet Union and China developed two water-soluble analogs: DMPS (also called unithiol) and DMSA (also called succimer). These agents work by the same basic principle as BAL, binding arsenic via sulfur groups, but they are less toxic to the patient and do not redistribute arsenic into the brain, a real concern with BAL.5PubMed Central. The role of chelation in the treatment of arsenic and mercury poisoning – Section: Abstract
DMSA is available as an oral capsule, which is a major practical advantage. A patient who can swallow medication does not need painful intramuscular injections. DMSA has been used successfully in acute arsenic cases; in one documented case of severe poisoning, intravenous DMSA was administered when oral dosing was not feasible, and the infusion was well tolerated.6PubMed. Acute arsenic poisoning treated by intravenous dimercaptosuccinic acid (DMSA) and combined extrarenal epuration techniques DMPS is also given orally or intravenously and shares similar advantages over BAL.
The tradeoff is that DMSA and DMPS are better at promoting arsenic excretion through the kidneys but have a harder time reaching arsenic that has already lodged inside cells.4PubMed Central. Chelation in metal intoxication This makes them excellent at mopping up arsenic circulating in the blood but potentially less effective at extracting arsenic that has already penetrated deep into tissue. In practice, physicians sometimes use BAL first to stabilize a critically ill patient, then switch to oral DMSA or DMPS once the patient can tolerate it, combining the strengths of both approaches.
Why Minutes and Hours Matter
Chelation therapy is most effective when started within minutes to hours of arsenic exposure. The longer the delay, the more arsenic binds irreversibly to tissues and the less a chelator can do.7Journal of Occupational and Environmental Medicine. Arsenic Exposure, Assessment, Toxicity, Diagnosis, and Management Chelation is typically reserved for patients with severe acute toxicity for this reason: by the time chronic, low-level exposure is discovered, the arsenic has been depositing in tissues for weeks or months, and chelators have far less to grab onto.
This timing issue creates a practical challenge. Arsenic poisoning symptoms in the first hours, especially from ingestion, overlap heavily with ordinary gastroenteritis: violent vomiting, watery diarrhea, and abdominal cramps. A patient who arrives at an emergency room with these symptoms and no clear history of arsenic exposure might not receive chelation until blood or urine tests come back, and by then the window has narrowed. Clinicians working in regions where arsenic exposure is common tend to have a lower threshold for starting chelation empirically, while physicians elsewhere may not suspect arsenic until organ damage becomes apparent.
Supportive Care Beyond the Antidote
Chelation addresses the arsenic itself, but arsenic poisoning attacks multiple organ systems simultaneously, and a chelating drug alone cannot manage the cascade of damage. Severe cases require aggressive supportive care that is every bit as important as the antidote.
The gastrointestinal tract takes the first hit after ingestion, with fluid losses from vomiting and diarrhea severe enough to cause dangerous dehydration and electrolyte imbalances. Intravenous fluid resuscitation is standard. If the patient is unconscious or vomiting uncontrollably, airway protection becomes a priority to prevent aspiration. GI decontamination, sometimes using activated charcoal if the patient presents early enough, is also part of the initial approach.8PubMed Central. Acute Arsenic Poisoning: A Case Report and Literature Review – Section: Abstract
The kidneys are especially vulnerable to arsenic. Acute kidney failure is a common complication of severe poisoning, and when the kidneys shut down, the body loses its primary route for excreting the chelator-arsenic complex. In these cases, hemodialysis serves a dual purpose: it replaces the kidneys’ filtering function and helps physically remove arsenic from the blood. In one reported case of massive arsenic ingestion, early hemodialysis was credited as a key factor in the patient’s survival, with chelation started on the second day after the initial dialysis sessions stabilized the patient.9PubMed. Massive arsenic poisoning–effect of hemodialysis and dimercaprol on arsenic kinetics
N-acetylcysteine (NAC), a drug better known as the antidote for acetaminophen overdose, has been used as an adjunctive therapy in some arsenic cases. NAC replenishes glutathione, a natural antioxidant that arsenic depletes. In one case report, NAC was administered alongside chelation and dialysis, and the patient recovered with improved kidney function after three sessions of sustained low-efficiency dialysis.8PubMed Central. Acute Arsenic Poisoning: A Case Report and Literature Review – Section: Abstract NAC’s role is considered adjunctive rather than primary, but it highlights how treatment for serious arsenic poisoning involves managing oxidative damage alongside removing the metal itself.
The Special Problem of Arsine Gas
Not all arsenic poisoning responds to the same playbook. Arsine gas is a colorless, highly toxic compound that can be released during industrial processes like smelting or semiconductor manufacturing. Inhaled arsine causes a completely different clinical picture from ingested arsenic: it destroys red blood cells, leading to massive hemolysis, dark-colored urine from the breakdown products, and kidney failure driven by the sheer volume of cellular debris clogging the renal system.
Standard chelation agents are not effective against arsine poisoning. There is, in fact, no known specific antidote for acute arsine toxicity.10PubMed. Arsine toxicity treated with red blood cell and plasma exchanges Treatment focuses on exchange transfusion, where the patient’s damaged blood is removed and replaced with healthy donor blood, along with dialysis to manage the inevitable kidney failure. Arsine poisoning is relatively rare, but it remains one of the most lethal forms of arsenic exposure precisely because the treatment options are so limited.
Risks and Limitations of Chelation Itself
Chelation drugs are not harmless tools. Beyond the well-known side effects of BAL, all chelation agents carry the risk of stripping essential metals from the body along with the toxic ones. A chelator designed to grab arsenic can also bind zinc, copper, or iron, and depleting those metals causes its own set of problems. In situations requiring long-term chelation, this risk of essential metal depletion becomes a serious limiting factor.11PubMed Central. Molecular mechanisms of in vivo metal chelation: implications for clinical treatment of metal intoxications
There is also an important distinction between chelation for acute poisoning and the unregulated “chelation therapy” marketed by some alternative medicine practitioners for vague complaints like chronic fatigue or autism. The clinical evidence supporting chelation is specific to documented heavy metal poisoning with measurable levels in blood or urine. Using chelation drugs outside that context carries all the risks with none of the established benefit, and cases of harm, including fatal hypocalcemia from EDTA chelation, have been reported in alternative medicine settings. If you do not have confirmed heavy metal poisoning, chelation is not a detox.
How the Body Handles Arsenic on Its Own
Your body is not completely defenseless against arsenic. The liver contains an enzyme called AS3MT (arsenic methyltransferase) that converts inorganic arsenic into methylated forms, which are less reactive with tissue and easier to excrete through urine.12PubMed Central. Metabolism, toxicity and anticancer activities of arsenic compounds – Section: Abstract This methylation pathway is the body’s primary natural detoxification route for arsenic.
The efficiency of this process varies between individuals and, fascinatingly, between populations. Research on indigenous communities in the Argentinean Andes, where drinking water has been naturally high in arsenic for thousands of years, found that these populations methylate and excrete arsenic more efficiently than other groups. Genome-wide analysis revealed strong selection pressure on the AS3MT gene in these communities compared with a closely related Peruvian population living in a region with lower arsenic exposure. This represents the first documented case of human adaptation to a toxic chemical.13Molecular Biology and Evolution. Human Adaptation to Arsenic-Rich Environments – Section: Abstract Whether this genetic adaptation extends to other Andean populations exposed to high arsenic is still being investigated.14PubMed. Human adaptation to arsenic in Bolivians living in the Andes
For most people, though, the methylation pathway simply cannot keep up with a large acute dose. It handles background-level exposure from food and water reasonably well, but when someone swallows a concentrated dose of arsenic trioxide, the enzyme system is overwhelmed within minutes. That is the gap chelation therapy fills.
Nanoparticle Delivery and the Future of Chelation
One of the frustrations with current chelation drugs is the tradeoff between safety and tissue penetration. BAL reaches deep tissues but causes significant side effects. DMSA and DMPS are gentler but less effective at extracting arsenic already inside cells. Researchers have been trying to split this difference, and one promising approach involves wrapping chelation agents in nanoparticles.
In animal studies, a modified form of DMSA called MiADMSA (monoisoamyl DMSA) encapsulated in solid lipid nanoparticles showed enhanced chelating ability compared with the same drug given in standard form. Rats treated with the nanoparticle version had greater reversal of oxidative stress markers and more efficient arsenic removal from blood and tissues.15PubMed. Nanoencapsulation of DMSA monoester for better therapeutic efficacy of the chelating agent against arsenic toxicity A follow-up study specifically examining neurological damage found that the nanoparticle formulation also led to better recovery in neurobehavioral measures, suggesting it reached the brain more effectively than the bulk drug.16PubMed. Comparative efficacy of Nano and Bulk Monoisoamyl DMSA against arsenic-induced neurotoxicity in rats
These are rat studies, and the leap from animal experiments to human medicine is always uncertain. But the concept is elegant: use nanoparticle packaging to sneak a water-soluble chelator past cell membranes it normally could not cross, combining the safety profile of DMSA-type agents with tissue penetration closer to what BAL achieves. No nanoparticle chelation agent has entered clinical trials for arsenic poisoning in humans yet.
Chronic Exposure and the Limits of Antidotes
Most arsenic poisoning worldwide is not a single dramatic ingestion but rather years of drinking contaminated groundwater, particularly in parts of Bangladesh, West Bengal, Vietnam, and parts of the American West. Chronic exposure produces a different pattern of disease: skin changes like darkening and thickening of the palms and soles, peripheral neuropathy, and increased risk of several cancers. Chelation therapy has a limited role here. By the time chronic poisoning manifests, arsenic has been integrated into tissues over years, and chelators cannot efficiently pull it out.
For chronic exposure, the most effective intervention is removing the arsenic source. Water filtration, switching to alternative water supplies, and in agricultural settings, changing rice cultivation methods to reduce arsenic uptake into grain are the strategies that actually lower the body burden over time. Research on rice farming, for instance, has shown that shifting from continuous flooding to irrigation methods that include dry periods can reduce grain arsenic by anywhere from 10 to 98 percent, depending on conditions. Choosing lower-arsenic rice varieties and applying silicon-based soil amendments also help.17PubMed Central. Agronomic solutions to decrease arsenic concentrations in rice
Researchers have also tested whether antioxidant supplementation could help people already showing signs of chronic arsenic toxicity. In a randomized, placebo-controlled trial in Bangladesh, participants with arsenical skin lesions received vitamin E, selenium, the combination, or placebo for six months. Supplementation slightly improved skin lesion scores, but the improvement was not statistically significant compared with placebo.18Journal of Occupational and Environmental Medicine. A Randomized, Double-Blind Placebo-Controlled Trial Evaluating the Effects of Vitamin E and Selenium on Arsenic-Induced Skin Lesions in Bangladesh A separate analysis from the same trial examined whether the supplements reduced a biomarker of protein oxidation, and again found no significant difference from placebo.19PubMed. Effect of selenium and vitamin e supplementation on plasma protein carbonyl levels in patients with arsenic-related skin lesions The evidence, in other words, does not support antioxidant supplements as a meaningful treatment for chronic arsenic damage. Clean water remains the intervention that works.
Why Arsenic Poisoning Still Happens
Arsenic poisoning persists not because we lack antidotes but because the circumstances that lead to exposure are so varied and so deeply embedded in geography, economics, and infrastructure. Deliberate poisoning grabs headlines, but the global burden falls overwhelmingly on communities with naturally arsenic-rich groundwater and no affordable alternative. An estimated 140 million people in at least 50 countries drink water with arsenic above the World Health Organization’s guideline level.
In acute poisoning scenarios, the medical toolkit is genuinely effective when deployed quickly: BAL or its successors, aggressive fluid support, dialysis if needed, and careful monitoring of the heart, liver, and kidneys. The challenge is access. Rural clinics in the most affected regions rarely stock chelation agents. Even in well-equipped hospitals, the diagnosis can be delayed because arsenic does not announce itself the way, say, a caustic burn does. Recognizing the pattern of symptoms, knowing the local exposure risks, and acting before organs begin to fail makes the difference between the antidote working and the antidote arriving too late.